New Releases from NCBI BookshelfLebrikizumab for treating moderate to severe atopic dermatitis in people 12 years and over.Lebrikizumab for treating moderate to severe atopic dermatitis in people 12 years and over.
Post Content
Uncategorized
New Releases from NCBI BookshelfNivolumab for adjuvant treatment of completely resected melanoma at high risk of recurrence in people 12 years and over (terminated appraisal).Nivolumab for adjuvant treatment of completely resected melanoma at high risk of recurrence in people 12 years and over (terminated appraisal).
Post Content
Uncategorized
New Releases from NCBI BookshelfEnabling 21st Century Applications for Cancer Surveillance Through Enhanced Registries and Beyond: Proceedings of a Workshop [Prepublication Draft].Enabling 21st Century Applications for Cancer Surveillance Through Enhanced Registries and Beyond: Proceedings of a Workshop [Prepublication Draft].
Population-based cancer surveillance has a pivotal role in assessing the nation’s progress in cancer control and helps inform research and
Uncategorized
New Releases from NCBI BookshelfNational Science, Technology, and Security Roundtable Capstone: Proceedings of a Workshop.National Science, Technology, and Security Roundtable Capstone: Proceedings of a Workshop.
The National Academies of Sciences, Engineering, and Medicine’s National Science, Technology, and Security Roundtable (NSTSR) was called for in the
Uncategorized
New Releases from NCBI BookshelfPembrolizumab with platinum- and fluoropyrimidine-based chemotherapy for untreated advanced HER2-negative gastric or gastro-oesophageal junction adenocarcinoma.Pembrolizumab with platinum- and fluoropyrimidine-based chemotherapy for untreated advanced HER2-negative gastric or gastro-oesophageal junction adenocarcinoma.
Post Content
Uncategorized
New Releases from NCBI BookshelfCombating Antimicrobial Resistance During the COVID-19 Pandemic: Perceived Risks and Protective Practices: Report [Internet].Combating Antimicrobial Resistance During the COVID-19 Pandemic: Perceived Risks and Protective Practices: Report [Internet].
The COVID-19 pandemic significantly disrupted efforts to combat antimicrobial resistance (AMR), undoing much of the progress achieved in recent years.
